Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk
Main finding · MACE, high CV risk groupResult — go to the resultHazard ratio 0.77 95 % CI 0.45–1.34Authors' conclusion
No significant differences in the risk of MACEs were observed between JAKi and TNFi users across various CV risk groups and in those with or without Hx.CVD.
Study context
- Population
- Patients with rheumatoid arthritis (RA) prescribed Janus kinase inhibitors (JAKi) or tumour necrosis factor inhibitors (TNFi) between 2015 and 2019, Korean nationwide claims database, stratified by cardiovascular (CV) risk
- Participants
- 7,575 patients
- Exposure
- JAKi vs TNFi
- Outcome
- MACE
Methodological detailsnationwide claims database, propensity score matching (up to 1:4) within CV risk strata, Cox proportional hazards model
- Nationwide claims database
- Propensity score matching (up to 1:4) within CV risk strata
- Cox proportional hazards model
Main finding
MACE, high CV risk group
Hazard ratio
0.77
95 % CI 0.45–1.34
JAKivs TNFi
HR 0.77 (95 % CI 0.45–1.34)
As reported in the abstract
Observational data: associations, not effects.
Further findings
MACE in patients with and without history of CVD (subgroup)
- No significant differences in major adverse cardiovascular events (MACEs) between JAKi and TNFi in Hx.CVD and non-Hx.CVD groups
Individual MACE components (MI, stroke, HF)
- No statistically significant differences in subgroup and sensitivity analyses
Original publication
Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk. Semin Arthritis Rheum. Published 9 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →